CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
chemotherapy +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01872819
NCT01872819N/ACompleted
CompareCT.gov

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

University of Washington·interventional·Posted Jun 7, 2013·Updated Jul 11, 2018

In Brief

A clinical study evaluating antitumor drug screening assay, chemotherapy, and 1 other intervention for Adult Acute Megakaryoblastic Leukemia (M7) and 18 related conditions. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This clinical trial uses a laboratory test called a high throughput sensitivity assay in planning treatment for patients with relapsed or refractory acute myeloid leukemia. The aim is to try to identify drugs that may be effective in killing leukemia cells for those patients who will not be cured with conventional chemotherapy. This assay will test multiple drugs simultaneously against a patient's own donated blood sample. The goal is to use this laboratory assay to best match a drug to a patient's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 7, 2013
Enrollment StartAug 2, 2013
Primary CompletionNov 1, 2014
Study CompletionNov 17, 2014
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.1 years ago

Interventions

antitumor drug screening assayother

Undergo high throughput drug sensitivity assay

chemotherapydrug

Patients receive 1 of 160 possible interventions

biological therapybiological

Patients receive 1 of 160 possible interventions